日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PROTACs therapeutically target the polyglutamine androgen receptor in spinal and bulbar muscular atrophy models.

PROTACs 以脊髓延髓肌萎缩症模型中的多聚谷氨酰胺雄激素受体为治疗靶点。

Sangotra Agamjot, Reddy Satya L, Kuo Curtis J, Xiang Weiguo, Merry Diane E, Grunseich Christopher, Wang Shaomeng, Lieberman Andrew P

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

发现 ARD-2585 是一种效力极强且口服有效的 PROTAC 雄激素受体降解剂,可用于治疗晚期前列腺癌

Xiang Weiguo, Zhao Lijie, Han Xin, Qin Chong, Miao Bukeyan, McEachern Donna, Wang Yu, Metwally Hoda, Kirchhoff Paul D, Wang Lu, Matvekas Aleksas, He Miao, Wen Bo, Sun Duxin, Wang Shaomeng

The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity

N-萘基环戊并[d]嘧啶的三维构象形状影响其作为微管靶向剂的效力及其抗肿瘤活性。

Xiang, Weiguo; Quadery, Tasdique M; Hamel, Ernest; Luckett-Chastain, Lerin R; Ihnat, Michael A; Mooberry, Susan L; Gangjee, Aleem

MCL-1 inhibition in cancer treatment

MCL-1抑制剂在癌症治疗中的应用

Xiang, Weiguo; Yang, Chao-Yie; Bai, Longchuan